Insilico Medicine and Fosun Pharma deliver second preclinical candidate for solid tumor treatment

Insilico Medicine Delivers Second Preclinical Candidate Compound for Solid Tumor Treatment

Introduction

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has announced the delivery of the second preclinical candidate compound (PCC) for the treatment of solid tumors. This collaboration with Fosun Pharma is utilizing synthetic lethal strategy, and the candidate is expected to be submitted for pre-IND application with the CDE in Q4 of 2024. In this article, we will explore the details of this collaboration and the innovative approach of using generative AI for drug discovery and development.

Background

Fosun Pharma proposed four targets of interest when initiating this collaboration. Insilico Medicine’s R&D team fully analyzed and validated the target through PandaOmics, an AI target identification engine, in combination with Life Star 1, an AI-driven robotics lab. Then, Chemistry42, a generative chemistry engine, was utilized to generate and design compounds from scratch for the specified target. In preclinical studies, the candidate demonstrated good selectivity, robust anti-tumor efficacy as well as promising ADMET properties.

Collaboration and Milestones

Insilico Medicine and Fosun Pharma’s collaboration began in January 2022, to proceed generative AI-driven drug discovery programs globally. After just one month, Insilico Medicine delivered the first PCC for QPCTL program, which is conducting a Phase I clinical trial in China and recently completed the first-in-patient dose for the treatment of advanced malignant tumors. Now, the second PCC milestone has been achieved, and Fosun Pharma will take over for further research and exploration once Insilico Medicine has advanced the candidate to the IND-enabling stage.

Impact and Potential

Candidates targeting DNA repair mechanisms play an increasingly important role in tumor therapy, making the potential treatment of solid tumors through synthetic lethal strategy a groundbreaking innovation. Insilico Medicine’s approach of using generative AI for the design of novel molecules is also a significant step forward in drug discovery and development. Powered by Pharma.AI, Insilico has nominated 18 preclinical candidates in its comprehensive portfolio of over 30 assets since 2021, and has received IND approval for 7 molecules.

Conclusion

The collaboration between Insilico Medicine and Fosun Pharma is a testament to the positive endorsement of AI-driven drug discovery in the pharmaceutical industry. The delivery of the second preclinical candidate compound for the treatment of solid tumors also showcases the potential of using generative AI for drug discovery and development. As an innovation-driven pharmaceutical company, Fosun Pharma strives to address unmet medical needs and enhance patient accessibility to safe and effective drugs through continuous innovation. Insilico Medicine’s goal is to take AI-driven drug discovery to the next level for the benefit of patients worldwide.

Long-tail Keywords

– Insilico Medicine
– Fosun Pharma
– Generative AI
– Drug discovery
– Preclinical candidate compound
– Synthetic lethal strategy
– Solid tumors
– DNA repair mechanisms
– Pharma.AI
– Pharmaceutical industry
– Innovation-driven
– Unmet medical needs
– Patient accessibility.

Originally Post From https://www.news-medical.net/news/20240705/Insilico-Medicine-and-Fosun-Pharma-deliver-second-preclinical-candidate-for-solid-tumor-treatment.aspx